Default company panoramic image

Epsilon Therapeutics

Drug discovery is based on deciphering anti-inflammatory mechanisms in human helminth infections, which are curative for chronic diseases

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Newton, MA, USA
  • Currency USD
  • Website

Company Summary

Epsilon Therapeutics partners with scientists in regions endemic for parasitic worm diseases to discover novel, non-toxic therapeutics for chronic inflammatory diseases. Up to 40% of Americans suffer from some form of chronic inflammation, including allergy, inflammatory bowel disease, and type 2 diabetes. Natural mechanisms, such as those mediated by parasitic worms, may be the key to developing highly effective and non-toxic therapeutics.


  • Default avatar
    Lisa Ganley-Leal

    Lisa Ganley-Leal is the founder of Epsilon Therapeutics. She is an immunologist with extensive experience in human disease and a demonstrated success in drug discovery. Epsilon recently received a grant from the Gates foundation to test profitability of drugs in emerging markets.


  • Default avatar
    Gil Arie; Foley Hoag